Autopsy report · NCT02489500

Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib

“Enrollment held for toxicity evaluation; then closed due to competing trial”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 1 year 10 months before it stopped.
• 3 participants enrolled.
• Results were posted on the registry 1 year 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Boston Medical Center

Sponsor type

University, hospital or other

Conditions

AL Amyloidosis

Interventions

Bortezomib; Melphalan; Neupogen; Stem Cell Collection; Stem cell infusion

Participants

3

Sites

1

Countries

United States

Trials that died the same way

• Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer
  “Closed to accrual to allow enrollment on another more promising trial.” (77% match in meaning)
• Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow
  “Closed prematurely due to emerging data on toxicity and competing trials.” (75% match in meaning)
• Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
  “the study was closed early due to competing trials” (72% match in meaning)
• Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
  “Due to study design (and toxicity), this trial closed to accrual prior to opening the phase II portion.” (69% match in meaning)
• Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q
  “"the study has been closed due to a low rate of patient enrollment (2 patients since the start of the trial)"” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.